Experiment 2 Results Sample Clauses

Experiment 2 Results. The results for agreement on the participle with postverbal coordinated sub- jects with uniform and mixed-gender conjuncts are presented in Figure 2 on page 208. The percentage for each data point is given in Table 4. Table 4. Experiment 2: Postverbal-Conjunct Agreement VS M F N MM 100% 0% 0% FF 3% 97% 0% NN 2% 0% 98% MF 100% 0% 0% MN 98% 0% 2% FM 10% 90% 0% NM 5% 0% 95% FN 5% 91% 4% NF 5% 2% 93%
Sample 1Sample 2
AutoNDA by SimpleDocs
Experiment 2 Results. The results for agreement on the participle with postverbal coordinated subjects, with uniform and mixed gender conjuncts, are presented in Figure 2. The percentage for each data point is given in Table 4. Figure 2: 100% Experiment 2: Postverbal Conjunct Agreement 90% 80% 70% 60% N 50% F 40% M 30% 20% 10% 0% MM FF NN MF MN FM NM FN NF 10 The total number of unambiguous instances for presented data are CCA (Conj2) = 1709 (59%), Def (ConjP) = 774 (26%) and HCA (Conj1) = 409 (14%). 11 The total number of unambiguous instances for presented data are masculine = 5416 (57%), neuter = 2286 (24%) and feminine = 1718 (18%). Table 4: Experiment 2: Postverbal Conjunct Agreement VS M F N MM 100% 0% 0% FF 3% 97% 0% NN 2% 0% 98% MF 100% 0% 0% MN 98% 0% 2% FM 10% 90% 0% NM 5% 0% 95% FN 5% 91% 4% NF 5% 2% 93% ConjP: Default agreement, i.e. masculine agreement on the predicate, can be unambiguously identified only in conditions where neither of the two conjuncts is masculine (otherwise it is confounded with masculine agreement with one of the conjuncts) – FF(M:3%), NN(M:2%), FN(M:5%) and NF(M:5%). Conj2: Distant-conjunct agreement. Distant conjunct agreement, i.e. gender of Conj2 on the predicate, can be transparently observed in mixed gender conditions where the second conjunct is not masculine – MF(F:0%), MN(N:2%), FN(N:4%) and NF(F:2%). Conj1: Closest- and Highest- conjunct agreement. CCA and HCA, i.e. gender of Conj1 on the predicate, can be transparently observed in mixed gender conditions where the first conjunct is not masculine – FM(F:90%), NM(N:95%), FN(F:91%) and NF(N:93%).
Sample 1

Related to Experiment 2 Results

  • Drug Test Results 1. All records pertaining to department-required drug tests shall remain confidential, and shall not be provided to other employers or agencies without the written permission of the person whose records are sought. However, medical, administrative, and immediate supervisory personnel may have access to relevant portions of the records as necessary to insure the acceptable performance of the officer's job duties.

  • Evaluation Results A. Evaluation results shall be used:

  • Test Results The employer, upon request from an employee or former employee, will provide the confidential written report issued pursuant to 4.9 of the Canadian Model in respect to that employee or former employee.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Justification and Anticipated Results The Privacy Act requires that each matching agreement specify the justification for the program and the anticipated results, including a specific estimate of any savings. 5 U.S.C. § 552a(o)(1)(B).

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Positive Test Results In the event an employee tests positive for drug use, the employee will be provided, in writing, notice of their right to explain the test results. The employee may indicate any relevant circumstance, including over the counter or prescription medication taken within the last thirty (30) days, or any other information relevant to the reliability of, or explanation for, a positive test result.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Results The five values obtained shall be arranged in order and the median value taken as a result of the measurement. This value shall be expressed in Newtons per centimetre of width of the tape. Annex 7 Minimum requirements for sampling by an inspector

Time is Money Join Law Insider Premium to draft better contracts faster.